Oncology & Cancer

Darolutamide boosts survival in nonmetastatic prostate cancer

(HealthDay)—For men with nonmetastatic, castration-resistant prostate cancer, the risk for death is significantly lower for those receiving darolutamide versus placebo, according to a study published in the Sept. 10 issue ...

Oncology & Cancer

Novel radiotracer meets gold standard for imaging prostate cancer

The novel radiopharmaceutical 18F-PSMA-1007 is both effective and readily available for detecting malignant prostate cancer lesions, according to research published in the April issue of The Journal of Nuclear Medicine. With ...

page 1 from 17